{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:41:04Z","timestamp":1787985664806,"version":"build-2784847793"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In excess of 90% of patients with polycythaemia vera (PV) express a mutated form of Janus kinase 2 (JAK2), JAK2V617F. Such aberrant proteins offer great potential for the treatment of these diseases; however, inhibitors to JAK2 have had limited success in the clinic in terms of curing the disease. To understand the effects of this oncogene in haematopoietic cells with the aim of improving treatment strategies, we undertook a systematic evaluation of the effects of JAK2V617F expression using proteomics. The effects of JAK2V617F on over 5000 proteins and 2000 nuclear phosphopeptide sites were relatively quantified using either SILAC or eight-channel iTRAQ mass spectrometry. Pathway analysis of the proteins identified as changing indicated disruption to the p53 and MYC signalling pathways. These changes were confirmed using orthogonal approaches. The insight gained from this proteomic analysis led to the formation of hypothesis-driven analysis on inhibitor-mediated effects on primary cells from patients with a JAK2V617F mutation. Simultaneous inhibition of MYC and upregulation of p53 led to the preferential extinction of JAK2V617F-positive CD34+ cells, illustrating a potential therapeutic benefit from combined targeting of p53 and MYC.<\/jats:p>","DOI":"10.1038\/leu.2017.143","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T06:40:40Z","timestamp":1495521640000},"page":"2717-2725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches"],"prefix":"10.1038","volume":"31","author":[{"given":"S","family":"Pearson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J K","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Blance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T C P","family":"Somervaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Azadbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A D","family":"Whetton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"BFleu2017143_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054\u20131061.","journal-title":"Lancet"},{"key":"BFleu2017143_CR2","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic J-P, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144\u20131148.","journal-title":"Nature"},{"key":"BFleu2017143_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387\u2013397.","journal-title":"Cancer Cell"},{"key":"BFleu2017143_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG . Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673\u2013683.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017143_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ajh.22063","volume":"86","author":"LM Scott","year":"2011","unstructured":"Scott LM . The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol 2011; 86: 668\u2013676.","journal-title":"Am J Hematol"},{"key":"BFleu2017143_CR6","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379\u20132390.","journal-title":"N Engl J Med"},{"key":"BFleu2017143_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391\u20132405.","journal-title":"N Engl J Med"},{"key":"BFleu2017143_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: 1140\u20131151.","journal-title":"PLoS Med"},{"key":"BFleu2017143_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1517\/14656566.2012.672974","volume":"13","author":"M Ohanian","year":"2012","unstructured":"Ohanian M, Cortes J, Kantarjian H, Jabbour E . Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 2012; 13: 927\u2013938.","journal-title":"Expert Opin Pharmacother"},{"key":"BFleu2017143_CR10","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016; 30: 1701\u20131707.","journal-title":"Leukemia"},{"key":"BFleu2017143_CR11","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/10428194.2016.1185783","volume":"57","author":"TI Mughal","year":"2016","unstructured":"Mughal TI, Abdel-Wahab O, Rampal R, Mesa R, Koschmieder S, Levine R et al. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma 2016; 57: 1517\u20131526.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017143_CR12","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian J-J, Al-Ali HK, Sirulnik A, Stalbovskaya V et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122: 4047\u20134053.","journal-title":"Blood"},{"key":"BFleu2017143_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799\u2013807.","journal-title":"N Engl J Med"},{"key":"BFleu2017143_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459\u2013468.","journal-title":"N Engl J Med"},{"key":"BFleu2017143_CR15","doi-asserted-by":"publisher","first-page":"e38928","DOI":"10.1371\/journal.pone.0038928","volume":"7","author":"A Pierce","year":"2012","unstructured":"Pierce A, Williamson A, Jaworska E, Griffiths JR, Taylor S, Walker M et al. Identification of nuclear protein targets for six leukemogenic tyrosine kinases governed by post-translational regulation. PLoS ONE 2012; 7: e38928.","journal-title":"PLoS ONE"},{"key":"BFleu2017143_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nprot.2015.007","volume":"10","author":"M Aspinall-O'Dea","year":"2015","unstructured":"Aspinall-O'Dea M, Pierce A, Pellicano F, Williamson AJ, Scott MT, Walker MJ et al. Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines. Nat Protoc 2015; 10: 149\u2013168.","journal-title":"Nat Protoc"},{"key":"BFleu2017143_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1074\/mcp.M200025-MCP200","volume":"1","author":"S-E Ong","year":"2002","unstructured":"Ong S-E, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002; 1: 376\u2013386.","journal-title":"Mol Cell Proteomics"},{"key":"BFleu2017143_CR18","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1074\/mcp.M112.024604","volume":"2013","author":"AJK Williamson","year":"2013","unstructured":"Williamson AJK, Pierce A, Jaworska E, Zhou C, Aspinall-O'Dea M, Lancashire L et al. A specific PTPRC\/CD45 phosphorylation event governed by stem cell chemokine CXCL12 regulates primitive hematopoietic cell motility. Mol Cell Proteomics 2013; 2013 12: 3319\u20133329.","journal-title":"Mol Cell Proteomics"},{"key":"BFleu2017143_CR19","doi-asserted-by":"publisher","first-page":"10739","DOI":"10.18632\/oncotarget.7639","volume":"7","author":"AD Whetton","year":"2016","unstructured":"Whetton AD, Che Azmi N, Pearson S, Jaworska E, Zhang L, Blance R et al. MPL W515L expression induces TGF\u03b2 secretion and leads to an increase in chemokinesis via phosphorylation of THOC5. Oncotarget 2016; 7: 10739\u201310755.","journal-title":"Oncotarget"},{"key":"BFleu2017143_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature08734","volume":"463","author":"K Naka","year":"2010","unstructured":"Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y et al. TGF-[bgr]-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676\u2013680.","journal-title":"Nature"},{"key":"BFleu2017143_CR21","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","volume":"107","author":"M Dong","year":"2006","unstructured":"Dong M, Blobe GC . Role of transforming growth factor-beta in hematologic malignancies. Blood 2006; 107: 4589\u20134596.","journal-title":"Blood"},{"key":"BFleu2017143_CR22","doi-asserted-by":"publisher","first-page":"10222","DOI":"10.1038\/ncomms10222","volume":"7","author":"M Leiva","year":"2016","unstructured":"Leiva M, Quintana JA, Ligos JM, Hidalgo A . Haematopoietic ESL-1 enables stem cell proliferation in the bone marrow by limiting TGF\u03b2 availability. Nat Commun 2016; 7: 10222.","journal-title":"Nat Commun"},{"key":"BFleu2017143_CR23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1182\/blood-2008-04-146480","volume":"113","author":"S Yamazaki","year":"2009","unstructured":"Yamazaki S, Iwama A, Takayanagi S-i, Eto K, Ema H, Nakauchi H . TGF-\u03b2 as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 2009; 113: 1250\u20131256.","journal-title":"Blood"},{"key":"BFleu2017143_CR24","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/blood-2012-05-356014","volume":"120","author":"V Pant","year":"2012","unstructured":"Pant V, Quint\u00e1s-Cardama A, Lozano G . The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood 2012; 120: 5118\u20135127.","journal-title":"Blood"},{"key":"BFleu2017143_CR25","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/onc.2011.313","volume":"31","author":"M Nakatake","year":"2012","unstructured":"Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E et al. JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2012; 31: 1323\u20131333.","journal-title":"Oncogene"},{"key":"BFleu2017143_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.stem.2012.05.020","volume":"11","author":"D-F Lee","year":"2012","unstructured":"Lee D-F, Su J, Ang Y-S, Carvajal-Vergara X, Mulero-Navarro S, Pereira Carlos F et al. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell 2012; 11: 179\u2013194.","journal-title":"Cell Stem Cell"},{"key":"BFleu2017143_CR27","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature08575","volume":"462","author":"R Lu","year":"2009","unstructured":"Lu R, Markowetz F, Unwin RD, Leek JT, Airoldi EM, MacArthur BD et al. Systems-level dynamic analyses of fate change in murine embryonic stem cells. Nature 2009; 462: 358\u2013U126.","journal-title":"Nature"},{"key":"BFleu2017143_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1752-0509-2-80","volume":"2","author":"M Hsing","year":"2008","unstructured":"Hsing M, Byler KG, Cherkasov A . The use of Gene Ontology terms for predicting highly-connected 'hub' nodes in protein-protein interaction networks. BMC Syst Biol 2008; 2: 80.","journal-title":"BMC Syst Biol"},{"key":"BFleu2017143_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0378-8733(78)90021-7","volume":"1","author":"LC Freeman","year":"1979","unstructured":"Freeman LC . Centrality in social networks conceptual clarification. Soc Networks 1979; 1: 215\u2013239.","journal-title":"Soc Networks"},{"key":"BFleu2017143_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.socnet.2010.03.006","volume":"32","author":"T Opsahl","year":"2010","unstructured":"Opsahl T, Agneessens F, Skvoretz J . Node centrality in weighted networks: generalizing degree and shortest paths. Soc Networks 2010; 32: 245\u2013251.","journal-title":"Soc Networks"},{"key":"BFleu2017143_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.molcel.2006.01.009","volume":"21","author":"B Benassi","year":"2006","unstructured":"Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 2006; 21: 509\u2013519.","journal-title":"Mol Cell"},{"key":"BFleu2017143_CR32","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1101\/gad.836800","volume":"14","author":"R Sears","year":"2000","unstructured":"Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR . Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501\u20132514.","journal-title":"Genes Dev"},{"key":"BFleu2017143_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","volume":"534","author":"SA Abraham","year":"2016","unstructured":"Abraham SA, Hopcroft LEM, Carrick E, Drotar ME, Dunn K, Williamson AJK et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature 2016; 534: 341\u2013346.","journal-title":"Nature"},{"key":"BFleu2017143_CR34","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844\u2013848.","journal-title":"Science"},{"key":"BFleu2017143_CR35","doi-asserted-by":"publisher","first-page":"U524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber J, Shi JW, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: U524\u2013U124.","journal-title":"Nature"},{"key":"BFleu2017143_CR36","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669\u201316674.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017143_CR37","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","volume":"126","author":"M Deininger","year":"2015","unstructured":"Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S . The effect of long-term ruxolitinib treatment on JAK2V617F allele burden in patients with myelofibrosis. Blood 2015; 126: 1551\u20131554.","journal-title":"Blood"},{"key":"BFleu2017143_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol.2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 2016; 101: 821\u2013829.","journal-title":"Haematologica"},{"key":"BFleu2017143_CR39","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.18632\/oncotarget.1951","volume":"5","author":"S-MA Huang","year":"2014","unstructured":"Huang S-MA, Wang A, Greco R, Li Z, Barberis C, Tabart M et al. Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms. Oncotarget 2014; 5: 3362\u20133374.","journal-title":"Oncotarget"},{"key":"BFleu2017143_CR40","first-page":"6230","volume":"19","author":"E Evrot","year":"2013","unstructured":"Evrot E, Ebel N, Romanet V, Roelli C, Andraos R, Qian Z et al. JAK1\/2 and pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Am Assoc Cancer Res 2013; 19: 6230\u20136241.","journal-title":"Am Assoc Cancer Res"},{"key":"BFleu2017143_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","volume":"124","author":"M Lu","year":"2014","unstructured":"Lu M, Xia L, Li Y, Wang X, Hoffman R . The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells. Blood 2014; 124: 771\u2013779.","journal-title":"Blood"},{"key":"BFleu2017143_CR42","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJMc1012718","volume":"364","author":"A Harutyunyan","year":"2011","unstructured":"Harutyunyan A, Klampfl T, Cazzola M, Kralovics R . p53 lesions in leukemic transformation. N Engl J Med 2011; 364: 488\u2013490.","journal-title":"N Engl J Med"},{"key":"BFleu2017143_CR43","doi-asserted-by":"publisher","first-page":"e52844","DOI":"10.1371\/journal.pone.0052844","volume":"8","author":"M Funakoshi-Tago","year":"2013","unstructured":"Funakoshi-Tago M, Sumi K, Kasahara T, Tago K . Critical roles of myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant. PLoS ONE 2013; 8: e52844.","journal-title":"PLoS ONE"},{"key":"BFleu2017143_CR44","first-page":"1194","volume":"13","author":"S Liu","year":"2014","unstructured":"Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA et al. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Ame Assoc Cancer Res 2014; 13: 1194\u20131205.","journal-title":"Ame Assoc Cancer Res"},{"key":"BFleu2017143_CR45","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","volume":"43","author":"D Szklarczyk","year":"2015","unstructured":"Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015; 43: D447\u2013D452.","journal-title":"Nucleic Acids Res"},{"key":"BFleu2017143_CR46","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498\u20132504.","journal-title":"Genome Res"},{"key":"BFleu2017143_CR47","doi-asserted-by":"publisher","first-page":"e1003731","DOI":"10.1371\/journal.pcbi.1003731","volume":"10","author":"R Janky","year":"2014","unstructured":"Janky R, Verfaillie A, Imrichova H, Van de Sande B, Standaert L, Christiaens V et al. iRegulon: from a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol 2014; 10: e1003731.","journal-title":"PLoS Comput Biol"},{"key":"BFleu2017143_CR48","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/bioinformatics\/btm554","volume":"24","author":"Y Assenov","year":"2008","unstructured":"Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M . Computing topological parameters of biological networks. Bioinformatics 2008; 24: 282\u2013284.","journal-title":"Bioinformatics"}],"updated-by":[{"DOI":"10.1038\/leu.2017.333","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017143","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:07:25Z","timestamp":1684433245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["BFleu2017143"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.143","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/leu.2017.333","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]},"assertion":[{"value":"16 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2017","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under a CC BY-NC-ND 4.0 license, but has now been made available under a CC BY 4.0 licence. The PDF and HTML versions of the paper have been modified accordingly","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}